Eaton Vance Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-21
Closed -$1K 2289
2021
Q2
$1K Buy
21
+7
+50% +$534 ﹤0.01% 2756
2021
Q1
$1K Buy
+14
New +$1.29K ﹤0.01% 2828

Other funds holding LKFT

Eaton Vance Management's LKFT Position: Q3 2021 in Review

Eaton Vance Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2021, closing a stake of 21 shares — an estimated $1K sold.

Eaton Vance Management first reported a position in LKFT in Q1 2021 and held it in 2 quarters. The position peaked at $1K in Q2 2021. 81 funds tracked by Wall St. Rank hold LKFT as of Q3 2021.

  • Eaton Vance Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2021 after selling out during the quarter.
  • Eaton Vance Management sold 21 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2021, an estimated $1K.
  • Eaton Vance Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 2 quarters.
  • Eaton Vance Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $1K in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2021.

Based on Eaton Vance Management's 13F filing for Q3 2021, filed 15 Nov 2021.